Cystic fibrosis is a chronic inflammatory disease. Most patients are affected by chronic obstructive lung disease associated with novel patterns of bacterial infection, particularly with Pseudomonas aeruginosa. Amongst the symptoms in CF patients is elevated serum levels of cystic fibrosis antigen, a complex of two S-100 proteins (S100A8 and S100A9; also commonly called MRP8 and MRP14) that are abundant in neutrophils and a subset of macrophages.
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The S100A8 and S100A9 proteins are found in the sera of both patients and heterozygous asymptomatic individuals. The observation that these proteins are also found expressed in the sera of patients with non-CF lung disease has been used to argue that their expression is a sequel to inflammation. 1 S100A8 mRNA has been shown elsewhere to be inducible in macrophages by bacterial lipopolysaccharide (LPS). 2 To determine whether CF antigen (S100A8/A9) could be induced in a response to infection in the lung, we examined the level of mRNA after intravenous injection of LPS. In control animals, S100A8 mRNA was almost undetectable in any tissue. Within 2 h of LPS injection, the level of mRNA was massively induced and was easily detected using total RNA from lung. Induction was maintained after 8 h. To dissect the sites of expression, we performed mRNA in situ hybridisation and immunocytochemistry. The former approach confirmed that S100A8 mRNA is widely expressed in the LPS-stimulated lung on a subset of cells with epithelial morphology lining alveoli, but is excluded from the bronchial epithelium. Immunolocalisation using anti-S100A8 antibody gave a different pattern, the only cells expressing high levels of S100A8 antigen had a location, morphology, and abundance consistent with their identity as interstitial and alveolar macrophages. The lack of correlation between mRNA and protein has been observed previously in studies of the trophoblasts (unpublished) and suggests that if the S100A8 protein is produced it may be rapidly secreted or in a complex that cannot be detected with the antibody.
The chronic pathology observed in CF has been attributed, in part, to inappropriate hyper-responsiveness to lung infection. We have produced a mouse transgenic line with the G551D mutation, 3 which has a somewhat less severe gastrointestinal phenotype than the more common human mutation ∆F508 or a complete null. We, therefore, compared the expression of S100A8 mRNA in CF G551D animals and wild-type litter-mates. The animals used in this study were specific pathogen-free and had no overt lung pathology. The majority of the CF animals had readily detectable S100A8 mRNA in the lung, whereas no such signal was detectable in any of the control animals. We injected groups of control and CF animals with LPS. Unlike the controls, which were not obviously affected by the treatment during the time course of the experiment, the CF animals displayed overt symptoms of endotoxaemia, hunched appearance, raised hair, sweating, and shivering. The level of S100A8 mRNA in the lungs of the LPS-treated CF animals was consistently substantially higher than in any of the control animals. Reprobing of these blots for expression of S100A9 revealed that it was similarly induced by LPS, and expressed at higher levels in unstimulated and LPStreated lungs from G551D CF mice. Hybridisation in situ of the S100A8 mRNA in the CF lungs revealed a much more extensive distribution than in wild type litter mates suggesting that, in part, the effect of the mutation is to increase the number of epithelial cells expressing the mRNA. The number of macrophage-like cells detected by immunolocalisation of the S100A8 protein was also increased; and increased expression per cell is not precluded because the labelling is not quantitative.
The major cell population that initiates LPS-mediated pathology is the macrophage, which expresses the receptor protein CD14. CFTR mRNA was detected by RT-PCR using RNA isolated from purified murine bone marrowderived macrophages (BMM) raising the possibility of a macrophage autonomous phenotype in CF. Both S100A8 and TNFα are LPS-inducible in BMM. In experiments comparing induction of these two mRNAs in BMM derived from litter-mates, those from CF homozygous mice responded most rapidly and to lower LPS concentrations. Most importantly, the heterozygous animals also exhibited increased susceptibility to LPS compared to wild type. The effect of the CF homozygous mutation of maximal levels of TNFα mRNA and protein has been confirmed using thioglycollate-elicited peritoneal macrophages.
In summary, we have shown that induction of S100A8/A9 mRNA is a lung-specific response to bacterial endotoxin and that CF mice are hypersensitive to LPS in terms of induction of this complex. We provide evidence that LPS hypersensitivity in CF is macrophage autonomous, and there is a phenotype in macrophages from heterozygous animals. The possibility that alveolar epithelial cells, which express S100A8 mRNA, are also hypersensitive to macrophage derived cytokines or direct effects of LPS is not precluded. The CF antigen dimer formed by S100A8 and S100A9 has been shown to be activated secreted and to have anti-microbial activity (see Rammes et al 4 ) so inducible secretion from epithelia, along with other defensins, may be a part of the lung antimicrobial defence. Previous workers have speculated upon a heterozygous advantage of the CF mutation in terms of resistance to enteric pathogens to explain the prevalence of mutant chromosomes in the Caucasian population. We suggest that the heterozygous state may also confer a more effective immune defence in the lungs. Enhanced defence against lung infection may be particularly relevant to fixation of CF mutations in the Caucasian population, who have evolved in climates in which lung diseases are a prevalent cause of early mortality. Recent studies have documented that LPS is brought to the membranes of responsive cells by the action of the lipid transport proteins, LBP and CD14. 1 This transport occurs in two steps. In the first, LBP attached to bacteria or LPS aggregates catalytically transfers an LPS monomer to a binding site on sCD14. sCD14 may then diffuse through the aqueous medium to the surface of a cell. The second essential step occurs at the cell surface and may involve either sCD14 or mCD14. sCD14 can interact directly with the cell surface, and this interaction predominates in cells that lack mCD14. In cells that express mCD14, the mCD14 may receive LPS monomers either by direct transfer from LPS aggregates mediated by LBP, or the LPS monomer may also be rapidly transferred from sCD14 to mCD14. In either case, the critical second step is release of LPS from CD14 into the lipid bilayer of cells. These two steps, binding of LPS monomer to CD14 and release of LPS monomer into the membrane, constitute the steps mediated by LBP and CD14 which appear necessary for cell stimulation. This assertion is strengthened by the observation that the need for LBP can be obviated by preforming LPS-sCD14 complexes, and the need for CD14 can be obviated by driving fusion of LPS into membranes either using fusogenic virosomes or very high concentrations of LPS. It should be noted that LPS aggregates and LPS-LBP complexes can be endocytosed by cells. In this setting, LPS remains topographically outside the cell (in lysosomes), and this process is not linked to stimulation of the inflammatory response: rather it represents a means for destroying LPS.
Innate recognition of bacterial LPS
The most important question in innate immunity is 'how do cells discriminate microbial lipids such as LPS from endogenous phospholipids?' Several lines of evidence indicate that neither LBP nor CD14 confers specificity in the interaction with LPS.
1 LPS can be discriminated from host lipids by cells in the absence of either LBP or CD14, and both LBP and CD14 show promiscuous interaction with a wide range of lipids in addition to biologically active LPS. It is, therefore, clear that the discrimination occurs after the fusion of LPS with the host plasma membrane. It is well known that cells recognize and sort lipids with subtle chemical differences, segregating sphingomyelin, for example, from the closely similar phosphatidyl choline. It is possible that similar types of lipid sorting might serve in innate recognition of microbial products. In keeping with this notion, we have noted that introduction of fluorescent LPS monomers into
